Microcap cardio player touts a 'sizable' tech deal with Bayer's BlueRock in wake of 'going concern' alert
A microcap biotech player operating under a “going concern” alert is touting a tie-up with Bayer’s BlueRock, a high-profile outfit exploring the frontiers of cell therapy R&D.
Sunnyvale, CA-based BioCardia says it nabbed a “sizable” upfront in the pact, which will put a catheter-based system it devised to deliver a patient’s bone marrow cells to heart muscle to use in BlueRock’s cardio work. BioCardia reported it won a breakthrough device award from the FDA on that.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.